- Investing Ideas
- South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
Results
7
Companies which are potentially undervalued and in an acceptable financial position.
7 companies
Hugel
Market Cap: ₩2.6t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩259,500.00
7D
0.6%
1Y
-31.3%
Dong-A Socio Holdings
Market Cap: ₩507.1b
Engages in the pharmaceutical business in South Korea.
A000640
₩78,000.00
7D
-7.3%
1Y
-28.5%
Dong-A ST
Market Cap: ₩322.0b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩33,900.00
7D
-9.0%
1Y
-26.9%
Daewoong Pharmaceutical
Market Cap: ₩1.3t
Develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
A069620
₩114,400.00
7D
-7.4%
1Y
-21.4%
PharmaResearch
Market Cap: ₩2.9t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩304,500.00
7D
0.8%
1Y
-36.6%
Hanmi Pharm
Market Cap: ₩4.8t
A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally.
A128940
₩403,000.00
7D
-9.7%
1Y
36.6%
ST PharmLtd
Market Cap: ₩2.4t
Provides manufacturing services for active pharmaceutical ingredient and intermediate.
A237690
₩121,000.00
7D
-9.0%
1Y
52.8%